HTA Information Hub
What is HTA? HTA stands for health technology assessment. It examines evidence about medicines, tests and other healthcare technologies to inform healthcare decisions, including those affecting access to treatment.
What would you like to understand?
You do not need previous HTA experience. Choose the route that is most relevant for you.
How does a new lupus medicine become available?
Hearing about a new medicine does not always mean you can get it where you live. Before that happens, different people look at different questions.
Can this medicine be sold?
Experts look at studies. They check whether the benefits are greater than the risks.
Allowing the medicine to be sold is called marketing authorisation.
How does it compare with other treatments?
Experts look at how well it works, its side effects and how it compares with care people already receive.
This kind of review is called health technology assessment (HTA).
Will people be able to get it in my country?
Countries make their own decisions about which treatments they provide and pay for.
When a health system pays for a medicine, this is often called reimbursement.
And where do patients come in?
People with lupus can explain what it is like to live with the illness. They can describe fatigue, pain, side effects and what matters in everyday life.
When can they contribute? When a particular treatment is being assessed, there may be set opportunities for patients or patient organisations to share their views. Sometimes this is early on, when the questions for the assessment are being decided; sometimes it is while the evidence is being reviewed. These opportunities are not open all the time, and the ways to take part and the deadlines differ between countries.
Good to know: A medicine can be approved for use without being paid for by every national health system. The steps and organisations involved also vary by country.
What is health technology assessment?
HTA, in plain language
Health technology assessment (HTA) is a structured way of evaluating health technologies, such as medicines, diagnostic tests and medical devices. It helps decision-makers consider questions such as which treatments should be offered, who might benefit from them and whether a health system should pay for them.
It considers evidence about how well a technology works and how safe it is. Depending on the setting, an assessment can also examine costs, organisational questions and the wider impact on patients and society.
Different health systems use this evidence in different ways. HTA informs decisions: it does not automatically determine whether a treatment is available to every patient.
Why do patient perspectives matter?
Clinical studies are essential, but they may not capture every aspect of living with lupus. Patients can help explain:
- Which symptoms and outcomes matter in daily life.
- The burden of existing treatments and side effects.
- What patients experience as unmet needs.
- Variation in needs, circumstances and experiences.
Three related, but distinct, decision processes
Can a medicine be marketed?
Regulators assess quality, safety and efficacy to decide whether a medicine may receive marketing authorisation. This is different from deciding whether a health system will pay for it.
What does the comparative clinical evidence show?
Under the EU HTA Regulation, joint clinical assessments are being introduced for specified technologies. They examine relative clinical effectiveness and safety, not national prices or reimbursement.
What happens in a particular health system?
National authorities remain responsible for decisions on use, pricing and reimbursement. Their methods, roles and opportunities for patient participation differ.
The EU framework has applied since 12 January 2025, with a phased expansion of its scope. Not all lupus medicines are currently subject to an EU joint clinical assessment. Countries outside the EU have their own arrangements. Check the European Commission’s overview ↗
Understanding HTA in your country
HTA processes are not identical across Europe. The organisations involved, the steps they follow and the opportunities to take part can differ from country to country.
Find a national HTA starting point
The European Commission lists national organisations participating in European joint HTA work. It is a useful place to identify an authority, although your country may have separate bodies responsible for reimbursement and access decisions.
EU coordination group ↗For national procedures, use the relevant authority’s own guidance.
Find a lupus organisation in your country
Start with a lupus organisation in your country. National groups can offer local knowledge and help you find the right place to ask questions. Lupus Europe’s member directory links to participating organisations.
Find a national member ↗Lupus Europe Secretariat: secretariat@lupus-europe.org
What can patients add to HTA?
Clinical studies tell us important things about a treatment. People living with lupus can add another kind of knowledge: what the disease, existing care and possible improvements mean in everyday life. The way this input is requested depends on the assessment and the country.
Help identify what matters to patients
An assessment may measure disease activity, flares or organ function. Patients can help explain why fatigue, pain, the ability to study or work, treatment side effects and reducing steroid use also matter.
For example: If a study shows improved disease activity, does it also show whether people can do more in their daily lives?
Explain why experiences vary
Lupus does not affect everyone in the same way. People may have different organ involvement, disease severity, treatment histories and support needs. These differences can help explain which patient groups an assessment needs to consider.
For example: Does the evidence reflect people with lupus nephritis, or people who have already tried several treatments?
Describe the reality of current treatment
Patients can describe the practical demands of living with treatment: multiple medicines, appointments, monitoring, side effects, or difficulties getting care. This helps others understand the existing situation against which a new approach is being considered.
For example: What does taking several medicines, or living with long-term steroid side effects, mean in practice?
Share experience through the appropriate process
Depending on the HTA body, participation might mean an interview, a questionnaire, an invitation to contribute as an individual patient expert, or a written submission from an organisation. Not every process offers all these routes.
A useful starting point: Find the relevant national process and check whether, when and how patient contributions are invited.
Not sure where to begin?
You can find a lupus organisation in your country or read the European Commission’s guidance on patient and carer participation in EU joint HTA work. At EU level, individual patient experts are selected under specific rules, including declarations of interests and confidentiality requirements.
PICO: four questions behind a clinical assessment
When someone asks, “Does this treatment work better?”, a useful next question is: better than what, for whom, and in which ways? PICO is a framework used to make that question precise. The letters stand for Population, Intervention, Comparator and Outcomes.
Who is the assessment about?
All people with lupus, or a particular group, such as people with active systemic lupus erythematosus (SLE), or with lupus nephritis (lupus affecting the kidneys)? Do differences in organ involvement, disease severity or previous treatment matter?
What is being assessed?
The treatment or other health technology being evaluated. For a medicine, this includes how it is intended to be used and for which patients.
What is it being compared with?
Existing care, another treatment or an appropriate alternative. In lupus, current care may include combinations of medicines and ongoing corticosteroid treatment.
What changes are being measured?
These might include flares, disease activity, organ protection or side effects. Patients may also want to know about fatigue, pain, daily functioning and whether steroid exposure can be reduced.
Why this matters: PICO does not tell us whether a medicine should be used. It helps everyone understand the precise question being assessed and whether the outcomes and patient groups considered reflect what matters in lupus.
What do people living with lupus report?
Lupus Europe provides patient-reported information through large multi-country surveys. The country-level reports help readers explore experiences of living with lupus in particular European countries.
Living with Lupus in 2020
These longer country reports describe respondents’ experiences of symptoms, diagnosis, treatment, work, family life and the practical burden of lupus. They can provide context for discussions about unmet needs and everyday impact.
Country-level survey findingsSwiss Knife Survey 2024
These shorter country reports look at symptoms, the burden of lupus, treatment satisfaction, unmet needs and communication with healthcare teams. They can help identify patient priorities that assessments should understand.
Country-level survey findingsOnly countries with published country-level reports are listed.
Available country reports
Select a country to open the available original PDF reports.
From a survey finding to a useful question
In the Swiss Knife Survey 2024 France country report, 67.3% of the 428 respondents answering the unmet-needs question selected less fatigue as an unmet need.
What outcomes would show whether a treatment makes a meaningful difference to patients’ fatigue and daily functioning?
What this supports: fatigue was a frequently reported unmet need among these survey respondents. What it does not establish: that any particular medicine reduces fatigue, or that the results represent everyone with lupus in France. Read the source factsheet ↗
Using these reports responsibly: country reports describe those who responded to each survey. Sample sizes and denominators vary by country and question; participation may not be representative of all people with lupus. The two surveys asked different questions, so differences between years should not be treated as trends without methodological assessment. Original reports and publications provide the necessary context.
Visit the complete Lupus Europe libraryExplore HTA information materials
Explore a small collection of curated information about HTA, patient involvement, training, official guidance and practical tools. Each resource opens the provider’s own website.
Nothing matches that search. Try a different keyword or select “All resources”.
Common questions, explained
Frequently asked questions
I am completely new to HTA. Where should I start?
Start with the essentials. If you want more detail, the resource library includes introductory materials from the European Commission and EUPATI. You do not need specialist knowledge to begin learning.
Is HTA the same as medicine approval?
No. Regulatory approval concerns whether a medicine can be marketed. HTA examines evidence to inform decisions about how technologies should be used, including national coverage and reimbursement decisions.
Does an EU joint clinical assessment determine reimbursement?
No. EU joint clinical assessment reports analyse comparative clinical evidence. National authorities continue to decide on pricing, reimbursement and use in their health systems.
Can a patient organisation participate in every assessment?
Participation routes and eligibility differ by authority and procedure. In EU joint work, selected individual patients and carers contribute as experts. Some national processes also invite submissions or expert nominations from patient organisations.
Can Lupus Europe surveys demonstrate that a treatment works?
No. They describe patients’ experiences and priorities, which can help identify important questions and unmet needs. Clinical effectiveness requires appropriately designed clinical evidence.
Can a volunteer receive more HTA training through Lupus Europe?
Lupus Europe has developed lupus-specific HTA training for national member organisations and their volunteers. Please contact the Secretariat for information on possible learning opportunities.
Small glossary
Health technology assessment: structured evaluation to support decisions about health technologies.
The EU Health Technology Assessment Regulation.
Joint clinical assessment: EU-level comparative clinical evidence analysis for technologies in scope.
Population, Intervention, Comparator, Outcomes: a framework for defining clinical assessment questions.
A health system’s arrangements for covering or paying for a treatment.
Information provided by patients about experiences, symptoms, needs and outcomes.
Regulatory permission for a medicine to be marketed. This is not the same as a reimbursement decision.
The treatment or care against which another option is compared.
Keep learning
Further develop your HTA knowledge
Start with the information and courses in our curated resource library.
Lupus Europe has also developed HTA training specifically for its national member organisations and their volunteers. Get in touch with us to find out more.
Learning from specialists
EUPATI (the European Patients’ Academy on Therapeutic Innovation) develops education for patients about medicines and HTA. EUCAPA (European Capacity Building for Patients) offers structured HTA courses, including introductory options. Explore their materials to find a suitable starting point.
Course dates, availability and eligibility are controlled by the providers.
Independence and purpose: This page provides information and learning resources.

